Warnex Inc. Appoints New Director: Richard Lacombe

LAVAL, QUEBEC--(Marketwire - April 28, 2010) - Warnex Inc. (TSX: WNX) is pleased to announce that, following it Annual General Meeting of Shareholders, Dr. Richard Lacombe has joined the Board of Directors of Warnex.

"It is with great pleasure that we welcome Dr. Lacombe to Warnex's Board of Directors," said Mark Busgang, President and CEO of Warnex. "With Dr. Lacombe's extensive experience in the pharmaceutical and CRO sectors, his understanding of these industries and his insight will be very valuable for Warnex."

Dr. Richard Lacombe is a consultant with over 30 years of experience with pharmaceutical, biotech, and contract research organization (CRO) companies. Dr. Lacombe was Vice-President, Clinical Affairs of BioSyntech Inc. from 2006 to 2008. He worked as an independent consultant for biotech companies from 2004 to 2006, and was President and Chief Executive Officer of Virocell Inc. from 2002 to 2004. Dr. Lacombe obtained a Ph.D. in Pharmacology from University of Montreal and a M.B.A. from University of Sherbrooke.

About Warnex

Warnex (www.warnex.ca) is a life sciences company devoted to protecting public health by providing laboratory services to the pharmaceutical and healthcare sectors. Warnex Analytical Services provides pharmaceutical and biotechnology companies with a variety of quality control services, including chemistry, chromatography, microbiology, method development and validation, and stability studies. Warnex Bioanalytical Services specializes in bioequivalence and bioavailability studies for clinical trials. Warnex Medical Laboratories provides specialized testing for the healthcare industry as well as pharmaceutical and central laboratory services. Warnex PRO-DNA Services offers DNA identification tests for paternity, maternity and other family relationships, as well as for immigration and forensic testing purposes. Warnex has three facilities located in Laval and Blainville, Quebec, and Thunder Bay, Ontario.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained in this news release are forward-looking and are subject to numerous risks and uncertainties, known and unknown. For information identifying known risks and uncertainties, relating to financial resources, liquidity risk, key customers and business partners, credit risk, foreign currency risk, government regulations, laboratory facilities, volatility of share price, employees, suppliers, and other important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the heading Risks and Uncertainties in Warnex's most recent Management's Discussion and Analysis, which can be found at www.sedar.com. Consequently, actual results may differ materially from the anticipated results expressed in these forward-looking statements.